ClinicalTrials.gg
Enrolling by invitationNCT06190470Updated Mar 8, 2024

Effects of Marijuana on Neuropathic Pain and Spasticity in Spinal Cord Injury Patients

A Phase 1 interventional study of Cannabis and Placebo in Spinal Cord Injury, sponsored by Khon Kaen University. Enrolling by invitation at 1 site in Thailand. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Khon Kaen University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Spinal Cord Injuries with a site in Thailand — 2 open to participants now, 2 under way, none of them phase 3. Spinal Cord Injuries · Thailand.

Started
2024
with 2 others
Phase 1
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
6 of 10
Khon Kaen University

Among the 10 studies in Spinal Cord Injuries with a site in Thailand, this one is one of 3 that started in 2024, is the only one in phase 1, and was the 8th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

2 of the 10 studies in Spinal Cord Injuries with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Spinal Cord Injuries with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare effects of marijuana or cannabis on neuropathic pain and spasticity in spinal cord injury patients. The main question is: Does the cannabis product from KhonKaen University reduce neuropathic pain and spasticity in spinal cord injury patients? The research design is a crossover study. The participants will be randomly into 2 groups: group 1 and group 2. The participants received either cannabis or placebo for 2 weeks. After completing treatment, participants were swapped to the other group for 2 weeks, a wash-out period is 2 weeks. The outcome measurements are pain and spasticity.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Cannabis
  • Marijuana
  • Spinal cord injury
  • Pain
  • Spasticity
04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spinal cord injury more than 6 months
  • Neuropathic pain
  • Pain score > 3
  • Do not response to standard medical treatment
  • Given inform consent

Exclusion criteria

Exclusion Criteria:

  • Allergy to cannabis
  • Unstable cardiovascular and pulmonary diseases
  • Chronic kidney and liver diseases
  • Psychological disease
  • Pregnancy or breastfeeding
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Experimental group

    The participants will receive cannabis product for 2 weeks. The participants will receive the cannabis product (THC 30mg / 1 ml) manufactured by Faculty of pharmaceutical science KhonKaen University. The participants will gradually increase using the product starting from 1 drop (1.5 mg THC) per day sublingually and can increase using not more than 1 drop per day, until pain or spasticity can be controlled.

    Drug: Cannabis

  • Placebo comparator
    Placebo group

    The participants will receive placebo product manufactured by Faculty of Pharmaceutical Science KhonKaen University for 2 weeks. The participants will gradually increase using the product starting from 1 drop per day sublingually and can increase using not more than 1 drop per day,

    Drug: Placebo

Interventions

  • DrugCannabis sativa subsp. indica TOPStudies of Cannabis sativa subsp. indica TOPCannabis sativa subsp. indica TOP pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.

    Also known as: Marijuana

  • DrugPlacebo

    Placebo is similar to Cannabis product but do not contain THC.

    Also known as: Control/ No cannabis

06

What researchers measure

Primary outcomes

  1. Pain score

    Visual analog scale

    Time frame: 2 weeks

Secondary outcomes

  1. Spasticity

    Modified Asworth Score

    Time frame: 2 weeks

  2. Activities of daily living

    to assess functional outcome

    Time frame: 2 weeks

  3. Quality of life score

    WHO Bref Quality of life questionnaire

    Time frame: 2 weeks

  4. H-reflex

    Electrodiagnosis

    Time frame: 2 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article after deidentification.

Supporting information: Study protocol, Clinical study report

Time frame: beginning 3 months and ending 5 years following article published

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2024, 5 months after the start.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Jan 2, 2024
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2024
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06190470
Responsible party
Nuttaset Manimmanakorn (Rehabilitation Medicine Department Faculty of Medicine, Khon Kaen University) — Principal investigator
First posted
Jan 5, 2024
Start date
Jan 2, 2024
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Mar 8, 2024

Study contacts

Nuttaset Manimmanakorn, MD, PhD
principal investigator · Rehabilitation Medicine Department, Faculty of Medicine, KhonKaen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabis sativa subsp. indica TOP

Start the discussion